Apomorphine (Onapgo) vs SER-252 (PEOZ-apomorphine)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: Dopamine receptor (non-ergoline agonist) · full Parkinson's Disease pipeline

Apomorphine (Onapgo)

Marketed by Supernus Pharmaceuticals and partners

Approved in Parkinson's Diseasesmall molecule
Reliable signal

NCT02006121 · Phase 3 · completed

The 12-week blinded phase randomized 107 participants to apomorphine or saline placebo, with participants, care providers, investigators, and outcome assessors masked. The primary clinical endpoint was met: apomorphine produced a greater reduction in daily OFF time than placebo, with a reported p-value of 0.0047, although substantial numbers did not complete the blinded phase.

Reported efficacy

Mean Change in Daily OFF Time From Baseline (Start of Blinded Treatment) to the End of Double-blind Phase (Visit 10) Based on Patient Diaries Using MMRM mITT Population (Baseline and 12 weeks): Mean Change in Daily OFF Time From Baseline (Start of Blinded Treatment) to the End of Double-blind Phase (Visit 10) Based on Patient Diaries Using MMRM mITT Population (Baseline and 12 weeks): Apomorphine Hydrochloride -2.61 Hours (95% CI -3.43 to -1.8) vs Placebo -0.75 Hours (95% CI -1.66 to 0.16) (met)

Result source: NCT02006121

SER-252 (PEOZ-apomorphine)

Developed by Serina Therapeutics

Phase 1 in Parkinson's Diseasesmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: January 2027 · NCT07422675 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointApomorphine (Onapgo)SER-252 (PEOZ-apomorphine)
OFF time, change-2.6 vs -0.8−1.9 vs placebowk 12 · n 53NCT02006121—Not reported
ON time without troublesome dyskinesia, change—Not reported—Not reported
UPDRS Part III, change—Not reported—Not reported
MDS-UPDRS Part II, change—Not reported—Not reported

OFF time, change

Apomorphine (Onapgo)
-2.6 vs -0.8−1.9 vs placebowk 12 · n 53NCT02006121
SER-252 (PEOZ-apomorphine)
—Not reported

ON time without troublesome dyskinesia, change

Apomorphine (Onapgo)
—Not reported
SER-252 (PEOZ-apomorphine)
—Not reported

UPDRS Part III, change

Apomorphine (Onapgo)
—Not reported
SER-252 (PEOZ-apomorphine)
—Not reported

MDS-UPDRS Part II, change

Apomorphine (Onapgo)
—Not reported
SER-252 (PEOZ-apomorphine)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

SER-252 (PEOZ-apomorphine): no structured comparison results are available for Parkinson's Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Apomorphine (Onapgo): 4 of 4 rows · SER-252 (PEOZ-apomorphine): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricApomorphine (Onapgo)
Dropout rate
22.2%
NCT02006121 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Discontinued due to AEs
11.1%
NCT02006121 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Serious AEs
23.5%
NCT02006121 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Most frequent reported AEs
infusion site nodule 46.9% (placebo 0%)
nausea 20.4% (placebo 9.4%)
somnolence 19.4% (placebo 3.8%)
NCT02006121 · Phase 3 · monotherapy · Parkinson's Disease · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Apomorphine (Onapgo)

OFF Time -2.61 vs -0.75 placebo hours @ 12wk
absolute change · hours
NCT02006121 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Daily on Time Without Troublesome Dyskinesia 2.9 vs 0.85 placebo hours @ 12wk
absolute change · hours
NCT02006121 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
PGIC 79.1% (n=43) vs 23.5% (n=34) placebo @ 12wk
responder rate · % of participants
NCT02006121 · Phase 3 · monotherapy · Parkinson's Disease · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Apomorphine (Onapgo)'s landscape · SER-252 (PEOZ-apomorphine)'s landscape